Pharmacy Chains Sue Allergan Over Restasis 'Anticompetitive Scheme'

A coalition of the nation's largest pharmacies are suing Allergan over what they alleged is a multiyear anticompetitive scheme to shield the company's dry eye drug Restasis from generic competition. While the plaintiffs are asking the court to enjoin Allergan from further anti-competitive conduct, it's unclear how the case, if decided in the pharmacies' favor, would affect Allergan's ongoing fight to shield Restasis from inter partes review. Allergan has been widely criticized for its decision to sell its Restasis patents...